CJ Bioscience Statistics

Total Valuation

CJ Bioscience has a market cap or net worth of KRW 123.73 billion. The enterprise value is 90.02 billion.

Market Cap	123.73B
Enterprise Value	90.02B

Important Dates

The next estimated earnings date is Thursday, March 20, 2025.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

CJ Bioscience has 13.07 million shares outstanding. The number of shares has increased by 45.44% in one year.

Current Share Class	n/a
Shares Outstanding	13.07M
Shares Change (YoY)	+45.44%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	3.54%
Owned by Institutions (%)	0.09%
Float	4.51M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	21.77
PB Ratio	1.80
P/TBV Ratio	3.47
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.16
EV / Sales	22.69
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.29

Financial Position

The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.18.

Current Ratio	3.11
Quick Ratio	3.01
Debt / Equity	0.18
Debt / EBITDA	n/a
Debt / FCF	-0.31
Interest Coverage	-43.88

Financial Efficiency

Return on equity (ROE) is -36.64% and return on invested capital (ROIC) is -29.09%.

Return on Equity (ROE)	-36.64%
Return on Assets (ROA)	-24.98%
Return on Capital (ROIC)	-29.09%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.05
Inventory Turnover	17.39

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -36.01% in the last 52 weeks. The beta is 0.95, so CJ Bioscience's price volatility has been similar to the market average.

Beta (5Y)	0.95
52-Week Price Change	-36.01%
50-Day Moving Average	10,708.00
200-Day Moving Average	12,425.40
Relative Strength Index (RSI)	40.55
Average Volume (20 Days)	34,413

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CJ Bioscience had revenue of KRW 3.97 billion and -21.62 billion in losses. Loss per share was -2,370.64.

Revenue	3.97B
Gross Profit	392.58M
Operating Income	-31.45B
Pretax Income	-21.62B
Net Income	-21.62B
EBITDA	-26.96B
EBIT	-31.45B
Loss Per Share	-2,370.64

Full Income Statement

Balance Sheet

The company has 42.23 billion in cash and 8.51 billion in debt, giving a net cash position of 33.71 billion or 2,580.28 per share.

Cash & Cash Equivalents	42.23B
Total Debt	8.51B
Net Cash	33.71B
Net Cash Per Share	2,580.28
Equity (Book Value)	48.07B
Book Value Per Share	5,275.11
Working Capital	29.97B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -26.30 billion and capital expenditures -1.04 billion, giving a free cash flow of -27.34 billion.

Operating Cash Flow	-26.30B
Capital Expenditures	-1.04B
Free Cash Flow	-27.34B
FCF Per Share	-2,092.84

Full Cash Flow Statement

Margins

Gross Margin	9.90%
Operating Margin	-792.92%
Pretax Margin	-544.89%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CJ Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-45.44%
Shareholder Yield	-45.44%
Earnings Yield	-25.03%
FCF Yield	-22.10%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CJ Bioscience has an Altman Z-Score of 0.77. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.77
Piotroski F-Score	n/a